Effects of adjuvant tamoxifen therapy on cardiac disease: Results from a randomized trial with long-term follow-up

Breast Cancer Research and Treatment

Volumn 138, Issue 2, 2013, Pages 467-473

  Rosell, Johan ^a,b   Nordenskjöld, Bo ^b   Bengtsson, Nils Olof ^c   Fornander, Tommy ^d   Hatschek, Thomas ^d   Lindman, Henrik ^e   Malmström, Per Olof ^f   Wallgren, Arne ^g   Stål, Olle ^b   Carstensen, John ^b  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

^g SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adjuvant treatment; Adverse events; Breast cancer; Coronary heart disease; Heart failure; Tamoxifen

Indexed keywords

TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CARDIOVASCULAR RISK; CAUSE OF DEATH; CONTROLLED STUDY; DRUG EFFECT; EARLY CANCER; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; POSTOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; RISK REDUCTION; SURVIVAL TIME; SWEDEN; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEART DISEASES; HUMANS; INCIDENCE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; TAMOXIFEN;

EID: 84879418031     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2457-6     Document Type: Article

References (26)

1. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717 (Pubitemid 40719106)
2. Rössner S, Wallgren A (1984) Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 52:339-346 (Pubitemid 14065052)
3. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF (2003) Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 18:937-947 (Pubitemid 37510624)
4. Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A (2007) Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99:272-282 (Pubitemid 47073490)
5. Nordenskjöld B, Rosell J, Rutqvist LE, Malmström PO, Bergh J, Bengtsson NO, Hatschek T, Wallgren A, Carstensen J (2005) Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial. J Natl Cancer Inst 97:1609-1610 (Pubitemid 41662715)
6. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, Heurgren M, Olausson PO (2011) External review and validation of the Swedish national inpatient register. BMC Public Health 11:450
7. Gupta S, Tandon VR, Kapoor B, Gupta A, Gupta GD, Khajuria V (2006) Effects of tamoxifen therapy on plasma lipid profile in patients of breast cancer. J Assoc Physicians India 54:183-186 (Pubitemid 43449792)
8. Powles TJ, Tillyer CR, Jones AL, Ashley SE, Treleaven J, Davey JB, McKinna JA (1990) Prevention of breast cancer with tamoxifen - an update on the Royal Marsden Hospital Pilot Programme. Eur J Cancer 26:680-684 (Pubitemid 20275099)
9. Cushman M, Costantino JP, Tracy RP, Song K, Buckley L, Roberts JD, Krag DN (2001) Tamoxifen and cardiac risk factors in healthy women: suggestion of an anti-inflammatory effect. Arterioscler Thromb Vasc Biol 21:255-261 (Pubitemid 32125375)
10. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR (2002) Comparison of c-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347:1557-1565 (Pubitemid 35315836)
11. Kardys I, de Maat MP, Uitterlinden AG, Hofman A, Witteman JC (2006) C-reactive protein gene haplotypes and risk of coronary heart disease: the Rotterdam Study. Eur Heart J 27:1331-1337 (Pubitemid 43998108)
12. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ (1995) Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial. BMJ 311:977-980
13. Rutqvist LE, Mattsson A (1993) Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 85:1398-1406 (Pubitemid 23264348)
14. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N (2005) Tamoxifen for the prevention of breast cancer: current status of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 97:1652-1662 (Pubitemid 41672231)
15. Melichar B, Kalábová H, Krcmová L, Urbánek L, Hyspler R, Solichová D, Melicharová K, Pecka M, Zadák Z (2009) Effect of aromatase inhibitors on lipid metabolism, inflammatory response and antioxidant balance in patients with breast carcinoma. Anticancer Res 29:3337-3346
16. Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A (2011) Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 103:1299-1309
17. Teerlink JR, Goldhaber SZ, Pfeffer MA (1991) An overview of contemporary etiologies of congestive heart failure. Am Heart J 121:1852-1853
18. Fox KF, Cowie MR, Wood DA, Coats AJ, Gibbs JS, Underwood SR, Turner RM, Poole-Wilson PA, Davies SW, Sutton GC (2001) Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J 22:228-236 (Pubitemid 32622473)
19. Kannel WB, Abbot RD (1984) Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham Study. N Engl J Med 311:1144-1147 (Pubitemid 14012581)
20. Kannel WB (1986) Silent myocardial ischemia and infarction: insights from the Framingham Study. Cardiol Clin 4:583-591 (Pubitemid 17230678)
21. Kardys I, Knetsch AM, Bleumink GS, Deckers JW, Hofman A, Stricker BH, Witteman JC (2006) C-reactive protein and risk of heart failure. The Rotterdam study. Am Heart J 152:514-520 (Pubitemid 44233424)
22. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, Sawyer DB, Levy D, Wilson PW, D'Agostino RB (2003) Inflammatory markers and risk of heart failure in eldery subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 107:1486-1491 (Pubitemid 36378485)
23. Williams ES, Shah SJ, Ali S, Na BY, Schiller NB, Whooley MA (2008) C-reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary heart disease: heart and Soul Study. Eur J Heart Fail 10:63-69
24. Mouridsen H, Keshaviah A, Coates AS, Rabaglio M, Castiglione-Gertsch M, Sun Z, Thürlimann B, Mauriac L, Forbes JF, Paridaens R, Gelber RD, Colleoni M, Smith I, Price KN, Goldhirsch A (2007) Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol 25:5715-5722
25. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA (1994) Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham heart study. JAMA 271:840-844
26. Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL, Brown P, Cuzick J, Kramer BS, Lippman SM (2009) American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27:3235-3258